[go: up one dir, main page]

AR105267A1 - Anticuerpos de unión a tau - Google Patents

Anticuerpos de unión a tau

Info

Publication number
AR105267A1
AR105267A1 ARP160102045A ARP160102045A AR105267A1 AR 105267 A1 AR105267 A1 AR 105267A1 AR P160102045 A ARP160102045 A AR P160102045A AR P160102045 A ARP160102045 A AR P160102045A AR 105267 A1 AR105267 A1 AR 105267A1
Authority
AR
Argentina
Prior art keywords
seq
tau
antibodies
joint
binding
Prior art date
Application number
ARP160102045A
Other languages
English (en)
Inventor
Seward Baker Terence
Edward Ormonde Knight David
Courade Jean
Philippe - Downey Patrick
Mairet-Coello Georges
Anthony Griffin Robert
James Mmillan David
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105267(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of AR105267A1 publication Critical patent/AR105267A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se refiere a anticuerpos de unión a Tau y fragmentos de unión de estos. Reivindicación 1: Un anticuerpo de unión a Tau aislado o un fragmento de unión de éste, caracterizado porque dicho anticuerpo de unión a Tau o fragmento de unión de este comprende: una región variable de cadena liviana que comprende una CDR1 seleccionada de la SEQ ID Nº 1, una CDR2 seleccionada de la SEQ ID Nº 2 y una CDR3 seleccionada de la SEQ ID Nº 3; y una región variable de cadena pesada que comprende una CDR1 seleccionada de la SEQ ID Nº 4, una CDR2 seleccionada de la SEQ ID Nº 5 y/o una CDR3 seleccionada de la SEQ ID Nº 6.
ARP160102045A 2015-07-06 2016-07-06 Anticuerpos de unión a tau AR105267A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06

Publications (1)

Publication Number Publication Date
AR105267A1 true AR105267A1 (es) 2017-09-20

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102045A AR105267A1 (es) 2015-07-06 2016-07-06 Anticuerpos de unión a tau

Country Status (25)

Country Link
US (4) US10287343B2 (es)
EP (1) EP3319983B1 (es)
JP (3) JP6630426B2 (es)
KR (2) KR102770650B1 (es)
CN (1) CN107849104B (es)
AR (1) AR105267A1 (es)
AU (1) AU2016289755C1 (es)
CA (1) CA2991451A1 (es)
CL (1) CL2018000043A1 (es)
CO (1) CO2017012971A2 (es)
EA (1) EA037092B1 (es)
EC (1) ECSP18000887A (es)
IL (1) IL256685B (es)
MA (2) MA41670A1 (es)
MX (1) MX2017015817A (es)
MY (1) MY193677A (es)
PE (1) PE20180481A1 (es)
PH (1) PH12017502207B1 (es)
SG (1) SG10202010735PA (es)
TN (1) TN2017000539A1 (es)
TW (1) TWI745295B (es)
UA (1) UA124616C2 (es)
UY (1) UY36773A (es)
WO (1) WO2017005734A1 (es)
ZA (1) ZA201800027B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
KR102770650B1 (ko) 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018221049A1 (en) 2017-02-17 2019-09-19 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
EP3894438A1 (en) 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
AU2020331020A1 (en) * 2019-08-13 2022-03-03 Washington University Methods to detect MTBR tau isoforms and use thereof
JP7399305B2 (ja) 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
EP4619416A1 (en) * 2022-11-14 2025-09-24 Washington University Methods to detect csf mtbr-tau and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025171285A1 (en) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Tau proteomimetics
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
EA201100527A1 (ru) 2008-09-26 2011-10-31 Юсб Фарма С.А. Биологические продукты
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
AU2009322044A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
JP2013506697A (ja) 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX347505B (es) 2011-09-19 2017-04-28 Axon Neuroscience Se Terapia basada en proteína y diagnóstico de patalogía mediada por tau en la enfermedad de alzheimer.
MX351502B (es) 2011-11-11 2017-10-18 Ucb Pharma Sa Anticuerpos de union de albumina y fragmentos de union de los mismos.
HRP20191342T1 (hr) 2011-12-20 2019-11-01 Janssen Biotech Inc Anti-phf-tau antitijela i njihove upotrebe
SG10201913370PA (en) * 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
CN111205368B (zh) 2012-12-21 2023-05-09 比奥根Ma公司 人抗-tau抗体
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
KR102770650B1 (ko) 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies

Also Published As

Publication number Publication date
JP2020055849A (ja) 2020-04-09
WO2017005734A1 (en) 2017-01-12
JP7413448B2 (ja) 2024-01-15
KR20250027278A (ko) 2025-02-25
AU2016289755C1 (en) 2021-08-19
PH12017502207A1 (en) 2018-06-11
MA41670A1 (fr) 2018-05-31
JP2022141689A (ja) 2022-09-29
TW201713689A (zh) 2017-04-16
CL2018000043A1 (es) 2018-05-18
CA2991451A1 (en) 2017-01-12
UA124616C2 (uk) 2021-10-20
EA201890172A1 (ru) 2018-10-31
IL256685B (en) 2022-02-01
CN107849104A (zh) 2018-03-27
US20190284267A1 (en) 2019-09-19
EP3319983A1 (en) 2018-05-16
US11732034B2 (en) 2023-08-22
ECSP18000887A (es) 2018-03-31
NZ738058A (en) 2021-07-30
UY36773A (es) 2017-01-31
JP2018524001A (ja) 2018-08-30
ZA201800027B (en) 2019-06-26
JP6630426B2 (ja) 2020-01-15
AU2016289755A1 (en) 2018-01-04
BR112017028102A2 (en) 2018-09-04
MY193677A (en) 2022-10-25
PH12017502207B1 (en) 2022-08-10
US20230416350A1 (en) 2023-12-28
US20210115121A1 (en) 2021-04-22
EA037092B1 (ru) 2021-02-04
CO2017012971A2 (es) 2018-03-09
JP7100008B2 (ja) 2022-07-12
PE20180481A1 (es) 2018-03-07
MA42377A (fr) 2018-05-16
AU2016289755B2 (en) 2020-12-03
US10287343B2 (en) 2019-05-14
IL256685A (en) 2018-03-29
HK1246804A1 (zh) 2018-09-14
CN107849104B (zh) 2021-08-27
TWI745295B (zh) 2021-11-11
EP3319983B1 (en) 2026-01-28
US20180201666A1 (en) 2018-07-19
KR102770650B1 (ko) 2025-02-19
US10889640B2 (en) 2021-01-12
MX2017015817A (es) 2018-04-10
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
SG10202010735PA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
AR105267A1 (es) Anticuerpos de unión a tau
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MX2025002735A (es) Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2020006213A (es) Anticuerpos anti-trem2 y metodos relacionados.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
CR20170026A (es) Anticuerpos anti-tau humanizados
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PE20190737A1 (es) Anticuerpos anti-cd27
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
PE20230381A1 (es) Proteina de union a rgma
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты

Legal Events

Date Code Title Description
FB Suspension of granting procedure